Description: BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
Home Page: www.briacell.com
BCTX Technical Analysis
Bellevue Centre
West Vancouver,
BC
V7T 2X1
Canada
Phone:
604 921 1810
Officers
| Name | Title |
|---|---|
| Dr. William V. Williams M.D. | CEO, Pres & Director |
| Mr. Gadi Levin B.Com., C.A., CPA, M.B.A., MBA | CFO & Corp. Sec. |
| Dr. Miguel A. Lopez-Lago | Chief Scientific Officer |
| Dr. Giuseppe Del Priore M.D., M.P.H., MPH | Chief Medical Officer |
| Dr. Charles Louis Wiseman FACP, M.D. | Founder, Principal Research Advisor & Member of Scientific Advisory Board |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 551.0001 |
| Price-to-Book MRQ: | 8.7288 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-02-24 |
| Fiscal Year End: | July |
| Full Time Employees: | 0 |